154 related articles for article (PubMed ID: 18460561)
21. Elevation of growth hormone secretagogue receptor type 1a mRNA expression in human growth hormone-secreting pituitary adenoma harboring G protein alpha subunit mutation.
Xu T; Ye F; Wang B; Tian C; Wang S; Shu K; Guo D; Lei T
Neuro Endocrinol Lett; 2010; 31(1):147-54. PubMed ID: 20150876
[TBL] [Abstract][Full Text] [Related]
22. Multiregional sampling reveals a homogenous distribution of Ki-67 proliferation rate in pituitary adenomas.
Wolfsberger S; Kitz K; Wunderer J; Czech T; Boecher-Schwarz HG; Hainfellner JA; Knosp E
Acta Neurochir (Wien); 2004 Dec; 146(12):1323-7; discussion 1327-8. PubMed ID: 15480830
[TBL] [Abstract][Full Text] [Related]
23. Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue?
Jallad RS; Musolino NR; Kodaira S; Cescato VA; Bronstein MD
Clin Endocrinol (Oxf); 2007 Aug; 67(2):310-5. PubMed ID: 17555503
[TBL] [Abstract][Full Text] [Related]
24. Cost of management of invasive growth hormone-secreting macroadenoma.
Luque-Ramírez M; Paramo C; Varela da Costa C; García-Mayor RV
J Endocrinol Invest; 2007; 30(7):541-5. PubMed ID: 17848835
[TBL] [Abstract][Full Text] [Related]
25. The role of stereotactic radiotherapy in patients with growth hormone-secreting pituitary adenoma.
Losa M; Gioia L; Picozzi P; Franzin A; Valle M; Giovanelli M; Mortini P
J Clin Endocrinol Metab; 2008 Jul; 93(7):2546-52. PubMed ID: 18413424
[TBL] [Abstract][Full Text] [Related]
26. Measurement of Ki-67 antigen in 159 pituitary adenomas using the MIB-1 monoclonal antibody.
Pizarro CB; Oliveira MC; Coutinho LB; Ferreira NP
Braz J Med Biol Res; 2004 Feb; 37(2):235-43. PubMed ID: 14762579
[TBL] [Abstract][Full Text] [Related]
27. Clinical implications of growth hormone-secreting tumor subtypes.
Kiseljak-Vassiliades K; Shafi S; Kerr JM; Phang TL; Kleinschmidt-DeMasters BK; Wierman ME
Endocrine; 2012 Aug; 42(1):18-28. PubMed ID: 22434413
[TBL] [Abstract][Full Text] [Related]
28. Biochemical remission and recurrence rate of secreting pituitary adenomas after transsphenoidal adenomectomy: long-term endocrinologic follow-up results.
Santoro A; Minniti G; Ruggeri A; Esposito V; Jaffrain-Rea ML; Delfini R
Surg Neurol; 2007 Nov; 68(5):513-8; discussion 518. PubMed ID: 17961741
[TBL] [Abstract][Full Text] [Related]
29. Pituitary macroadenomas (>3 cm) in young adulthood: Pathologic and proliferative characteristics.
Öngürü Ö; Düz B; Şimşek H; Günal A; Gönül E
Neurol Neurochir Pol; 2015; 49(4):212-6. PubMed ID: 26188936
[TBL] [Abstract][Full Text] [Related]
30. Pituitary adenomas treated with gamma knife radiosurgery: volumetric analysis of 100 cases with minimum 3 year follow-up.
Pamir MN; Kiliç T; Belirgen M; Abacioğlu U; Karabekiroğlu N
Neurosurgery; 2007 Aug; 61(2):270-80; discussion 280. PubMed ID: 17762739
[TBL] [Abstract][Full Text] [Related]
31. [Outcome of somatostatin analogue treatment in acromegaly].
Mondok A; Tóth M; Patócs A; Szücs N; Igaz P; Pusztai P; Czirják S; Beko G; Gláz E; Rácz K; Tulassay Z
Orv Hetil; 2009 Aug; 150(31):1457-62. PubMed ID: 19617182
[TBL] [Abstract][Full Text] [Related]
32. CD147 expression in pituitary adenomas and its significance for clinical outcome.
Qu X; Yang W; Jiang M; Han T; Han L; Qu Y; Wang G; Shi D; Xu G
Hum Pathol; 2010 Aug; 41(8):1165-71. PubMed ID: 20381119
[TBL] [Abstract][Full Text] [Related]
33. Nonfunctioning pituitary adenomas: association of Ki-67 and HMGA-1 labeling indices with residual tumor growth.
Šteňo A; Bocko J; Rychlý B; Chorváth M; Celec P; Fabian M; Belan V; Šteňo J
Acta Neurochir (Wien); 2014 Mar; 156(3):451-61; discussion 461. PubMed ID: 24452592
[TBL] [Abstract][Full Text] [Related]
34. An analysis of granulation patterns, MIB-1 proliferation indices and p53 expression in 101 patients with acromegaly.
Sarkar S; Chacko AG; Chacko G
Acta Neurochir (Wien); 2014 Dec; 156(12):2221-30; discussion 2230. PubMed ID: 25238988
[TBL] [Abstract][Full Text] [Related]
35. Assessment of sFRP4 as a bio-marker for predicting aggressiveness and recurrence of growth hormone-secreting pituitary adenomas.
Wu Y; Liu C; Yu S; Gao H; Li Z; Li C; Zhang Y
Oncol Rep; 2016 May; 35(5):2991-9. PubMed ID: 26935389
[TBL] [Abstract][Full Text] [Related]
36. Role of Ki-67 proliferation index and p53 expression in predicting progression of pituitary adenomas.
Gejman R; Swearingen B; Hedley-Whyte ET
Hum Pathol; 2008 May; 39(5):758-66. PubMed ID: 18439942
[TBL] [Abstract][Full Text] [Related]
37. Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria.
Kreutzer J; Vance ML; Lopes MB; Laws ER
J Clin Endocrinol Metab; 2001 Sep; 86(9):4072-7. PubMed ID: 11549628
[TBL] [Abstract][Full Text] [Related]
38. Markers of proliferation and invasiveness in somatotropinomas.
Baldys-Waligorska A; Wierzbicka I; Sokolowski G; Adamek D; Golkowski F
Endokrynol Pol; 2018; 69(2):182-189. PubMed ID: 29334118
[TBL] [Abstract][Full Text] [Related]
39. Effects of selective somatostatin analogs and cortistatin on cell viability in cultured human non-functioning pituitary adenomas.
Padova H; Rubinfeld H; Hadani M; Cohen ZR; Nass D; Taylor JE; Culler MD; Shimon I
Mol Cell Endocrinol; 2008 May; 286(1-2):214-8. PubMed ID: 18276067
[TBL] [Abstract][Full Text] [Related]
40. Ki-67 expression for predicting progression of postoperative residual pituitary adenomas: correlations with clinical variables.
Matsuyama J
Neurol Med Chir (Tokyo); 2012; 52(8):563-9. PubMed ID: 22976139
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
